

ASX RELEASE

1 March 2016

Allard Ruling to Boost Canadian Medical Cannabis System and Improve Patient Access

- Federal Court ruling gives Canadian Government six months to introduce new or parallel federal MC regime
- Ruling based on limitations to MC access resulting from current regime's prohibition on personal cultivation
- Resulting regulatory impact expected to be favorable for MMJ
- High profile ruling acts to further legitimise MC and has positive implications for both Canadian patients and MMJ

On February 24, a Federal Canadian Court ruled in favour of amending or replacing the Marijuana for Medical Purposes Regulations (MMPR) in Canada within six months. The decision in the Allard et al. v. Canada case was based on limitations to MC access imposed by the MMPR, including the prohibition of personal cultivation for patients with a prescription.

MMJ Welcomes Court Decision

MMJ views the court ruling as a very positive endorsement of MC in Canada and believes that it will ultimately result in a stronger, safer and more widely utilized Canadian MC system. In the ruling which will significantly enhance patient access to MC, the court acknowledged the therapeutic benefits of MC for Canadian patients but also expressed concern around harm associated with consumption via smoking the product.

In addition to the reforms discussed above, Trudeau's government has announced its intention to make cannabis available nationwide for recreational consumption. With these two significant reforms being undertaken in tandem, Canada will advance its position as a global leader in progressive, safe and responsible cannabis reform. MMJ welcomes the Allard ruling and is excited by the opportunity it presents as a leader in non-combustion delivery systems in a rapidly evolving market.

ASX RELEASE

MMJ Focus on Sophisticated Medical Delivery Technologies

Judge Phelan identified some of the MMJ's shortcomings with respect to limitations on permissible forms of MC stating, "The negative effects of the law include the forced ingestion of cannabis medicine by smoking or vaporisation with the attendant harms on account of the restrictions permissible forms of marijuana; and the removal of the benefits of oral and topical modes of ingestion." This regulatory trajectory is entirely congruent with MMJ's strategy to cater to a broader market through alternative delivery technologies that offer quality, safety and consistency without the harmful effects associated with smoking.

MMJ and Canadian Medical Consumers Growing Personally

MMJ maintains its support for all legal methods of cultivating medical cannabis whether commercial or personal. The United Greeneries' (UG) business plan to supply genetics and services like analytical testing and processing to other growers in Canada can now be extended to individual patients. Much like home brewed alcohol, the Company expects home growing to have little impact on demand for medical cannabis, which will provide greater quality, consistency and convenience to MC patients.

For more information, please contact:

Andreas Gedeon
Managing Director
MMJ Phytotech
+1 (250) 713 6302
agedeon@mmj.ca

Gaelan Bloomfield
Manager, Marketing & PR
MMJ Phytotech
+61 431 303 567
gbloomfield@mmj.ca

For media enquiries:

Whitney Fitzsimmons
Director Media & Communications
Market Eye
0448 285 646
Whitney.fitzsimmons@marketeye.com.au

ASX RELEASE

About MMJ PhytoTech Limited

MMJ PhytoTech is a medical cannabis company, which aims to commercialise medical cannabis and high potential cannabis-based therapeutics products to rapidly growing markets internationally with regulated MC industries. The Company operates three subsidiaries with operations across the entire medical cannabis value chain, encompassing the Company's "Farm to Pharma" strategy.

Its **United Greeneries** subsidiary has cultivation facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory. **Satipharm** has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.

The third subsidiary, **PhytoTech Therapeutics** based in Israel, has an exclusive research and licensing agreement with Yissum, the prestigious research, development and technology transfer company of Hebrew University in Jerusalem, a global leader in MC research.

<http://www.mmjphytotech.com.au>